Núcleo de Pesquisa Clínica da Rede São Camilo

São Paulo 04014-002

1 studies enrolling now · 7 studies all time

What they study most

Abiraterone Acetate, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cytochrome P-450, Enzyme Inhibitors, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists

Studies at this site

• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) — Completed
• A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer — Stopped early